Brachytherapy device developer Xoft has received FDA clearance for a new brachytherapy device designed to target breast cancer.
The Fremont, CA, company's Axxent electronic brachytherapy system delivers localized, nonradioactive isotope-free radiation treatment to the breast. The device can be turned on and off at will, enabling it to be used in minimally shielded settings and resulting in improved access to radiation therapy, according to the company.
By AuntMinnie.com staff writers
January 5, 2006
Related Reading
Varian, Xoft sign distribution deal, October 13, 2005
Xoft raises funding, June 2, 2003
Copyright © 2006 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
